Chemotherapy of cancer is still considered a complex phenomenon given that single chemotherapeutic agents cannot be administered for a long period of time because of the development of drug resistance and severe side effects. Nanodrug delivery systems (NDDSs) such as nanoparticles and liposomes are being investigated to enhance the safety and efficacy of anticancer agents. NDDS-based delivery of a single agent is not found to be effective in long-term anticancer therapy. Codelivery of more than one anticancer agent using liposomes shows great potential since it exhibits simultaneous synergistic therapeutic manifestations at the tumor site and enhances therapeutic efficacy in terms of the low-dose requirement of each agent and diminished side effects. Liposomes are lipid vesicles arranged in concentric bilayers with an aqueous core; they are versatile nanocarriers that accommodate the diverse nature of anticancer drugs (both hydrophobic and hydrophilic) at the same time. They offer a number of advantages for combinatorial drug delivery in terms of increased blood circulation, selective accumulation at tumor tissues, and stimuli responsiveness. Various combination of drugs such as paclitaxel (PTX) and topotecan, sunitinib and irinotecan, and combretastin A-4 and doxorubicin have been reported for cancer chemotherapy using liposomes. This review focuses on recent scenarios of combinatorial drug delivery using liposomes for better chemotherapeutic outcomes. This assemblage can be of great importance to researchers looking for advances in novel drug delivery approaches for better cancer treatment.

中文翻译：

---

使用多功能脂质体的联合癌症治疗。

考虑到由于产生耐药性和严重的副作用，不能长时间施用单一化疗药物，癌症的化疗仍然被认为是一个复杂的现象。正在研究纳米药物递送系统 (NDDS)，例如纳米颗粒和脂质体，以提高抗癌药物的安全性和有效性。未发现基于 NDDS 的单一药剂递送在长期抗癌治疗中有效。使用脂质体联合递送一种以上的抗癌剂显示出巨大的潜力，因为它在肿瘤部位表现出同时的协同治疗表现，并在每种药物的低剂量需求和减少的副作用方面提高了治疗效果。脂质体是排列成同心双层的脂质囊泡，具有水核；它们是多功能纳米载体，可同时适应抗癌药物（疏水性和亲水性）的多样性。它们在增加血液循环、肿瘤组织选择性积聚和刺激反应性方面为组合药物递送提供了许多优势。已经报道了多种药物组合，例如紫杉醇 (PTX) 和拓扑替康、舒尼替尼和伊立替康，以及考布他汀 A-4 和多柔比星用于使用脂质体的癌症化疗。本综述侧重于最近使用脂质体进行组合药物递送以获得更好的化疗结果的情况。这种组合对于寻求新型药物递送方法进展以更好地治疗癌症的研究人员来说非常重要。